安全性方面，研究中报告的最常见不良事件包括肌肉疼痛、疲劳、便秘、高血压和恶心。参考来源：‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’，新闻...
安全性方面,研究中报告的最常见不良事件包括肌肉疼痛、疲劳、便秘、高血压和恶心。 参考来源:‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’,新闻...
安全性方面,研究中报告的最常见不良事件包括肌肉疼痛、疲劳、便秘、高血压和恶心。 参考来源:‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’,新闻...
安全性方面,研究中报告的最常见不良事件包括肌肉疼痛、疲劳、便秘、高血压和恶心。 参考来源:‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’,新闻...
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.doi:10.1200/JCO.2024.42.4_suppl.526622111152#Background:Patients with BRCA+ mCRPC have an aggressive disease course. Recently, ...
3.U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer. Retrieved August 11, 2023 from https://www.janssen.com/fda-approves-akeega-niraparib-and...
参考来源:‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’,新闻发布。Johnson & Johnson;2023年8月11日发布。
参考来源:‘U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer’,新闻发布。Johnson & Johnson;2023年8月11日发布。
3.U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer. Retrieved August 11, 2023 from https://www./fda-approves-akeega-niraparib-and-abiraterone...
前列腺癌(Prostate-cancer)是全球男性第二大最常确诊的恶性肿瘤,大多数男性在确诊时患有局部前列腺癌,可通过手术或放疗进行治疗。前列腺癌细胞的生长具有雄激素依赖性,故患者最初对雄激素剥夺治疗(ADT)敏感,而经持续ADT后仍然发生疾病进展的患者会发展为mCRPC。据预估,约10-50%的患者在确诊后3年内进展为mCRPC,其中...